



SAFETY DATA SHEET

Revision Date 16-Jul-2019

Version 2

1. IDENTIFICATION OF THE SUBSTANCE/PREPARATION AND OF THE COMPANY/UNDERTAKING

Product identifier

Product Name Femcon Fe

Other means of identification

Product Code RM00010

Synonyms Norethindrone Acetate and Ethinyl Estradiol Tablets, USP and Ferrous Fumarate Tablets

Recommended use of the chemical and restrictions on use

Recommended Use Contraceptive Agent

This safety data sheet is written to provide health, safety and environmental information for people handling this formulated product in the workplace. It is not intended to provide information relevant to medicinal use of the product. In this instance patients should consult prescribing information/package insert/product label or consult their pharmacist or physician. For health and safety information for individual ingredients used during manufacturing, refer to the appropriate safety data sheet for each ingredient.

Details of the supplier of the safety data sheet

Manufacturer

Allergan plc
5 Giralda Farms
Madison, NJ USA 07940
+1-800-272-5525

E-mail address SDS@Allergan.com

Emergency telephone number

Emergency Telephone Call CHEMTREC Day or Night
Within USA or Canada: 1-800-424-9300
Outside USA and Canada: +1-703-741-5970 (collect calls accepted)

2. HAZARDS IDENTIFICATION

Classification

OSHA Regulatory Status

This chemical is considered hazardous by the 2012 OSHA Hazard Communication Standard (29 CFR 1910.1200)

Serious eye damage/eye irritation	Category 1
Germ cell mutagenicity	Category 2
Carcinogenicity	Category 1A
Reproductive toxicity	Category 2
Effects on or via lactation	Yes

Label elements

Emergency Overview

Danger

Hazard statements

H318 - Causes serious eye damage
H341 - Suspected of causing genetic defects
H350 - May cause cancer
H361 - Suspected of damaging fertility or the unborn child
H362 - May cause harm to breast-fed children



Appearance Tablet	Physical state Solid	Odor No information available
Chemical Name POVIDONE USP(PLASDONE K-29-32)	Symptoms Possible eye, skin, gastrointestinal and/or respiratory tract irritation. Possible allergic reaction to material if inhaled, ingested or in contact with skin. Overdose effects from ingestion of large amounts include abdominal cramps, flatulence, and fecal impaction.	
Ethinyl Estradiol	The most common effects from therapeutic use of products containing Ethinyl Estradiol are headache, menstrual disorder, breast pain, abdominal pain, nausea, flu syndrome, acne, vaginal moniliasis, depression, diarrhea, asthenia, dysmenorrhea, back pain, infection, pharyngitis, inter-menstrual bleeding, migraine, vomiting, dizziness, nervousness, vaginitis, sinusitis, cystitis, bronchitis, gastroenteritis, allergic reaction, urinary tract infection, pruritus, emotional lability, rash, upperrespiratory infection. Chronic toxicity increases the risk of cardiovascular disease, including myocardial infarction, cerebrovascular disease, thromboembolic disease, gallbladder disease, and certain cancers in some people. Chronic toxicity from Ethinyl Estradiol, like other estrogens, increases the risk for stroke, myocardial infarction and thromboembolic disease in certain populations. Jaundice, hypertension, nasal congestion, headache, dizziness and fluid retention may occur. Endometrial, breast, and certain liver cancers may occur at a higher incidence than the general population.	
Trosipium Chloride	The most common adverse reactions are dry mouth, constipation, and headache.	
Chemical Name POVIDONE USP(PLASDONE K-29-32)	Medical Conditions Aggravated by Exposure Known hypersensitivity to this medication	
Ethinyl Estradiol	Pre-existing skin conditions may be aggravated by repeated overexposures to this compound. This compound should not be used when pregnant. The following preexisting conditions may be aggravated by therapeutic doses of this compound: adrenal gland problems, heart disease, high blood pressure, breast cancer, diabetes, kidney/eye/nerve/blood vessel disease, severe headaches/migraines, heart disease, liver conditions and gallbladder disease.	
Trosipium Chloride	This medication is contraindicated in patients with: urinary retention, gastric retention, uncontrolled narrow-angle glaucoma, known hypersensitivity to the drug or its ingredients; angioedema, rash and anaphylactic reaction have been reported.	

Precautionary statements

P280 - Wear eye protection/ face protection

P305 + P351 + P338 - IF IN EYES: Rinse cautiously with water for several minutes. Remove contact lenses, if present and easy to do. Continue rinsing

P310 - Immediately call a POISON CENTER or doctor/physician

P202 - Do not handle until all safety precautions have been read and understood

P281 - Use personal protective equipment as required

P405 - Store locked up

P501 - Dispose of contents/ container to an approved waste disposal plant

P201 - Obtain special instructions before use

P260 - Do not breathe dusts or mists

P263 - Avoid contact during pregnancy/while nursing

P264 - Wash face, hands and any exposed skin thoroughly after handling

P270 - Do not eat, drink or smoke when using this product

P308 + P313 - IF exposed or concerned: Get medical advice/attention

Other Information

Unknown Acute Toxicity

62.01% of the mixture consists of ingredient(s) of unknown toxicity

Over the counter drugs in their solid form are considered exempt under the criteria of the Federal OSHA Hazard Communication Standard 20 CFR 1910.1200. However, in an industrial setting where a component's occupational exposure limit may be surpassed, than can be considered hazardous

3. COMPOSITION/INFORMATION ON INGREDIENTS

Chemical Name	CAS No.	EINECS	Weight-%
POVIDONE USP(PLASDONE K-29-32)	9003-39-8	N/A	7 - 13*
Norethindrone	68-22-4	200-681-6	1 - 5*
Ethinyl Estradiol	57-63-6	200-342-2	1 - 5*
Tropium Chloride	10405-02-4	233-875-4	0.1 - 1*
TALC USP(1656)	14807-96-6	238-877-9	0.1 - 1*

*The exact percentage (concentration) of composition has been withheld as a trade secret.

4. FIRST AID MEASURES

First aid measures

Eye contact	Rinse immediately with plenty of water and seek medical advice.
Skin Contact	Wash off immediately with soap and plenty of water while removing all contaminated clothes and shoes.
Inhalation	Remove to fresh air.
Ingestion	Consult a physician if necessary.

Chemical Name

Ethinyl Estradiol

Note to physicians

This material is contraindicated in women who have the following conditions: Thrombophlebitis or thromboembolic disorders, history of deep vein thrombophlebitis or thromboembolic disorders, cerebrovascular or coronary artery disease (current or history), valvular heart disease with thrombogenic complications, uncontrolled hypertension, diabetes with vascular involvement, headaches with focal neurological symptoms (such as aura), major surgery with prolonged immobilization, known or suspected carcinoma of the breast or personal history of breast cancer, carcinoma of the endometrium or other known or suspected estrogen-dependent neoplasia, undiagnosed abnormal genital bleeding, cholestatic jaundice of pregnancy or jaundice with prior pill use, hepatic adenomas or carcinomas, or active liver disease, known or suspected pregnancy, hypersensitivity to component of the product. Cigarette smoking increases the risk of serious cardiovascular side effects from oral contraceptive use. This risk increases with age and with the extent of smoking (in epidemiologic studies, 15 or more cigarettes per day was associated with a significantly increased risk) and is quite marked in women over 35 years of age. Women who use oral contraceptives should be strongly advised not to smoke. The use of oral contraceptives is associated with increased risk of several serious conditions including venous and arterial thrombotic and thromboembolic events (such as myocardial infarction, thromboembolism, and stroke), hepatic neoplasia, gallbladder disease, and hypertension, although the risk of serious morbidity or mortality is very small in healthy women without underlying risk factors. The risk of morbidity and mortality increases significantly in the presence of other underlying risk factors such as certain inherited thrombophilias hypertension, hyperlipidemias, obesity and diabetes.

Tropium Chloride

Tropium chloride is contraindicated in patients with urinary

retention, gastric retention, uncontrolled narrow-angle glaucoma, and known hypersensitivity to the drug or its ingredients. Angioedema, rash and anaphylactic reaction have been reported.

5. FIRE-FIGHTING MEASURES

Suitable extinguishing media

Use extinguishing measures that are appropriate to local circumstances and the surrounding environment.

Unsuitable extinguishing media

None known.

Specific hazards arising from the chemical

Fire may produce irritating, corrosive and/or toxic gases.

Explosion data

Sensitivity to Mechanical Impact Not impact sensitive.

Sensitivity to Static Discharge Fine dust dispersed in air, in sufficient concentrations, and in the presence of an ignition source is a potential dust explosion hazard.

Protective equipment and precautions for firefighters

As in any fire, wear self-contained breathing apparatus pressure-demand, MSHA/NIOSH (approved or equivalent) and full protective gear.

6. ACCIDENTAL RELEASE MEASURES

Personal precautions

Use personal protection recommended in Section 8. Do not touch damaged containers or spilled material unless wearing appropriate protective clothing.

Environmental precautions

See Section 12 for additional ecological information.

Methods for containment

Prevent further leakage or spillage if safe to do so.

Methods for cleaning up

Use personal protective equipment as required. Cover powder spill with plastic sheet or tarp to minimize spreading and keep powder dry. Take up mechanically, placing in appropriate containers for disposal. Avoid creating dust. Clean contaminated surface thoroughly.

7. HANDLING AND STORAGE

Advice on safe handling

Avoid contact with skin, eyes or clothing. Avoid generation of dust. Do not eat, drink or smoke when using this product.

Storage Conditions

Keep containers tightly closed in a dry, cool and well-ventilated place. Store away from incompatible materials.

Incompatible materials

None known based on information supplied.

8. EXPOSURE CONTROLS/PERSONAL PROTECTION

Control parameters

Exposure Guidelines

Chemical Name	ACGIH TLV	OSHA PEL	NIOSH IDLH	Allergan OEL (ug/m ³)
Ethinyl Estradiol 57-63-6	N/A	N/A	N/A	0.01 ug/m ³
Tropium Chloride 10405-02-4	N/A	N/A	N/A	100 ug/m ³
TALC USP(1656) 14807-96-6	TWA: 2 mg/m ³ particulate matter containing no asbestos and <1% crystalline silica, respirable particulate matter	(vacated) TWA: 2 mg/m ³ respirable dust <1% Crystalline silica, containing no Asbestos TWA: 20 mppcf if 1% Quartz	IDLH: 1000 mg/m ³ TWA: 2 mg/m ³ containing no Asbestos and <1% Quartz respirable dust	N/A

		or more;use Quartz limit	
--	--	--------------------------	--

NIOSH IDLH *Immediately Dangerous to Life or Health*

Other Information Vacated limits revoked by the Court of Appeals decision in AFL-CIO v. OSHA, 965 F.2d 962 (11th Cir., 1992).

Appropriate engineering controls

Engineering Controls The health hazard risks of handling this material are dependent on factors, such as physical form and quantity. Site specific risk assessments should be conducted to determine the appropriate exposure control measures. Good general ventilation should be used. Ventilation rates should be matched to conditions. If applicable, use process enclosures, local exhaust ventilation, or other engineering controls to maintain airborne levels below recommended exposure limits. If exposure limits have not been established, maintain airborne levels as low as reasonably achievable.

Individual protection measures, such as personal protective equipment

Eye/face protection No eye protection is normally needed during medical administration of this product. During operations in which dusts of the product may be generated, safety glasses should be considered.

Skin and body protection During medical administration of this product, medical latex or nitrile gloves should be worn to avoid absorption of the product. Use appropriate protective clothing for the task (e.g., lab coat, etc.).

Respiratory protection Respiratory protection is generally not needed during routine conditions of use of this product. If respiratory protection is needed, use only respiratory protection authorized under appropriate regional regulations.

9. PHYSICAL AND CHEMICAL PROPERTIES

Information on basic physical and chemical properties

Physical state	Solid	Appearance	Tablet
Color	No information available	Odor	No information available
Odor threshold	No information available		

<u>Property</u>	<u>Values</u>
pH	No information available
Melting point/freezing point	No information available
Boiling point / boiling range	No information available
Flash point	No information available
Evaporation rate	No information available
Flammability (solid, gas)	No information available
Flammability Limit in Air	
Upper flammability limit:	No information available
Lower flammability limit:	No information available
Vapor pressure	No information available
Vapor density	No information available
Specific Gravity	No information available
Water solubility	No information available
Solubility in other solvents	No information available
Partition coefficient	No information available
Autoignition temperature	No information available
Decomposition temperature	No information available
Explosive properties	No information available
Oxidizing properties	No information available

Other Information

Molecular weight	No information available
VOC Content (%)	No information available
Density	No information available
Bulk density	No information available

10. STABILITY AND REACTIVITY

Reactivity

Not defined As Reactive substance

Chemical stability

Stable under normal conditions.

Possibility of Hazardous Reactions

None under normal processing.

Conditions to avoid

Aerosol formation.

Incompatible materials

None known based on information supplied.

Hazardous Decomposition Products

None known based on information supplied.

11. TOXICOLOGICAL INFORMATION

Information on likely routes of exposure

Acute toxicity

Chemical Name	Inhalation	Eye contact	Skin Contact	Ingestion
Ethinyl Estradiol	Inhalation of airborne dusts generated by this product may slightly irritate the nose, throat, and lungs. Symptoms are generally alleviated upon breathing fresh air.	Contact with eyes may cause irritation.	Repeated or prolonged skin contact may cause allergic reactions with susceptible persons, Prolonged contact may cause redness and irritation, Contact with the skin may cause mild irritation, which is alleviated upon rinsing. Prolonged or repeated skin contact may cause dermatitis (dry, red skin).	If this compound is swallowed, CALL PHYSICIAN OR POISON CONTROL CENTER FOR MOST CURRENT INFORMATION. If professional advice is not available, do not induce vomiting. Rinse mouth with water immediately. Victim should drink large quantities of water. If milk is available, victim should drink it after drinking water. Never induce vomiting or give diluents (milk or water) to someone who is unconscious, having convulsions, or unable to swallow.
Trospium Chloride	If airborne dusts generated by this product are inhaled, remove victim to fresh air. If necessary, use artificial respiration to support vital functions. Seek medical attention if adverse effect continues after removal to fresh air.	Contact with the eyes of airborne dusts generated by this compound may cause mild to moderate irritation, redness, and tearing (mechanical irritation).	In therapeutic use, this compound has caused swelling of the skin, rash and anaphylactic reactions. Angioedema of the face, lips, tongue and/or larynx has been reported with therapeutic use of Trospium. Angioedema associated with upper airway swelling may be life threatening. May cause irritation to skin. Prolonged or repeated skin contact may cause dermatitis	If this compound is swallowed, CALL PHYSICIAN OR POISON CONTROL CENTER FOR MOST CURRENT INFORMATION. If professional advice is not available, do not induce vomiting. Rinse mouth with water immediately. Victim should drink large quantities of water. If milk is available, victim should drink it after drinking water. Never induce

			(dry, red skin).	vomiting or give diluents (milk or water) to someone who is unconscious, having convulsions, or unable to swallow.
--	--	--	------------------	--

Chemical Name	Oral LD50	Dermal LD50	Inhalation LC50
POVIDONE USP(PLASDONE K-29-32)	= 100 g/kg (Rat)	N/A	N/A
Ethinyl Estradiol	= 960 mg/kg (Rat)	N/A	N/A
Trospium Chloride	= 1510 mg/kg (Rat)	N/A	N/A

Delayed and immediate effects as well as chronic effects from short and long-term exposure

Chemical Name	Germ cell mutagenicity	Carcinogenicity	Reproductive toxicity	Effects on or via lactation
POVIDONE USP(PLASDONE K-29-32)	No information available.	Not suspected of being a human carcinogen.	No information available.	No information available
Ethinyl Estradiol	Estradiol induced DNA breaks in hamster renal cells, but not in hepatocytes.	There is sufficient evidence in humans for the carcinogenicity of post-menopausal estrogen therapy. There is sufficient evidence in experimental animals for the carcinogenicity of estradiol and estrone.	Studies in mice show prenatal exposure of ethinylestradiol induces reproductive abnormalities, including polyovular follicles, over-independent vaginal epithelial stratification and cornification. Exposure to ethinylestradiol also is linked to suppression of testicular testosterone levels, lower sperm head counts, lower weights of the testis, epididymis and prostate in rats.	Very small amounts are excreted in milk.
Trospium Chloride	Not mutagenic in the standard battery of tests.	Animal studies in mice and rats have not shown carcinogenicity.	Studies in rats and rabbits have not shown statistically significant levels of teratogenicity or harm to the fetus.	Detectable amounts of this compound have been identified in the milk of nursing women receiving this drug. Caution should be exercised when taking this compound is administered to nursing women.

Chemical Name	STOT - single exposure	STOT - repeated exposure
Ethinyl Estradiol	Toxicity is unlikely following acute single exposure of excessive amounts.	Acute poisoning results in mild, self-limiting effects, usually involving the gastrointestinal tract (GI). Chronic toxicity increases risk of cardiovascular disease, including myocardial infarction, cerebrovascular disease, thromboembolic disease, gallbladder disease, and certain cancers in some people.

Chronic toxicity Target Organ Effects May cause adverse liver effects. Contains a known or suspected reproductive toxin. Central nervous system, Eyes, Gastrointestinal tract (GI), liver, Reproductive System, Skin, Urinary Tract.

Numerical measures of toxicity - Product Information

Unknown Acute Toxicity 62.01% of the mixture consists of ingredient(s) of unknown toxicity
The following values are calculated based on chapter 3.1 of the GHS document .
ATEmix (oral) 4619 mg/kg
ATEmix (dermal) 30193 mg/kg

12. ECOLOGICAL INFORMATION

Ecotoxicity

86.25% of the mixture consists of component(s) of unknown hazards to the aquatic environment

Chemical Name	Algae/aquatic plants	Fish	Crustacea
---------------	----------------------	------	-----------

TALC USP(1656) 14807-96-6	N/A	100: 96 h Brachydanio rerio g/L LC50 semi-static	N/A
------------------------------	-----	---	-----

Chemical Name	Persistence and degradability	Bioaccumulation	Mobility	Partition coefficient
Ethinyl Estradiol 57-63-6	NOT READILY BIODEGRADABLE	No information available	Mobility in soil	3.67
Tropium Chloride 10405-02-4	No information available	No information available	No information available	Log P = 0.70

Other adverse effects No information available

13. DISPOSAL CONSIDERATIONS

Waste treatment methods

Disposal of wastes Disposal should be in accordance with applicable regional, national and local laws and regulations.

Contaminated packaging Do not reuse container. Dispose of contents/containers in accordance with local regulations.

14. TRANSPORT INFORMATION

DOT Not regulated

TDG Not regulated

ICAO (air) Not regulated

IATA Not regulated

IMDG Not regulated

ADR Not regulated

ADN Not regulated

15. REGULATORY INFORMATION

International Inventories

TSCA Not Listed
DSL/NDSL Not Listed
EINECS/ELINCS Not Listed

Legend:

TSCA - United States Toxic Substances Control Act Section 8(b) Inventory
DSL/NDSL - Canadian Domestic Substances List/Non-Domestic Substances List
EINECS/ELINCS - European Inventory of Existing Chemical Substances/European List of Notified Chemical Substances

US Federal Regulations

Carcinogenicity The table below indicates whether each agency has listed any ingredient as a carcinogen. This product contains one or more substances which are classified by IARC as carcinogenic to humans (Group I), probably carcinogenic to humans (Group 2A) or possibly carcinogenic to humans (Group 2B)

Chemical Name	ACGIH	IARC	NTP	OSHA
POVIDONE USP(PLASDONE K-29-32)	-	Group 3	-	-

9003-39-8				
Norethindrone 68-22-4	-	Group 2B	Reasonably Anticipated	X
Ethinyl Estradiol 57-63-6	-	Group 1	-	X
TALC USP(1656) 14807-96-6	-	Group 3	-	X

IARC (International Agency for Research on Cancer)
 Group 1 - Carcinogenic to Humans
 Group 2B - Possibly Carcinogenic to Humans
 Not classifiable as a human carcinogen
 NTP (National Toxicology Program)
 Known - Known Carcinogen
 Reasonably Anticipated - Reasonably Anticipated to be a Human Carcinogen
 OSHA (Occupational Safety and Health Administration of the US Department of Labor)
 X - Present

SARA 313

Section 313 of Title III of the Superfund Amendments and Reauthorization Act of 1986 (SARA). This product does not contain any chemicals which are subject to the reporting requirements of the Act and Title 40 of the Code of Federal Regulations, Part 372

SARA 311/312 Hazard Categories

Acute health hazard	Yes
Chronic Health Hazard	No
Fire hazard	No
Sudden release of pressure hazard	No
Reactive Hazard	No

CWA (Clean Water Act)

This product does not contain any substances regulated as pollutants pursuant to the Clean Water Act (40 CFR 122.21 and 40 CFR 122.42)

CERCLA

This material, as supplied, does not contain any substances regulated as hazardous substances under the Comprehensive Environmental Response Compensation and Liability Act (CERCLA) (40 CFR 302) or the Superfund Amendments and Reauthorization Act (SARA) (40 CFR 355). There may be specific reporting requirements at the local, regional, or state level pertaining to releases of this material

US State Regulations

California Proposition 65

This product contains the following Proposition 65 chemicals

Chemical Name	California Proposition 65
Norethindrone - 68-22-4	Carcinogen Developmental
Ethinyl Estradiol - 57-63-6	Carcinogen Developmental
MICROCRYSTALLINE CELLULO(AVICEL PH102) - 9004-34-6	Carcinogen

U.S. State Right-to-Know Regulations

Chemical Name	New Jersey	Massachusetts	Pennsylvania
MICROCRYSTALLINE CELLULO(AVICEL PH102) 9004-34-6	X	X	X
FERRIC OXIDE NF (RED 30) 1309-37-1	X	X	X
TALC USP(1656) 14807-96-6	X	X	X
CORN STARCH NF 9005-25-8	-	X	X
White Cresin Wax 8002-74-2	X	X	X

16. OTHER INFORMATION

Revision Date 16-Jul-2019
Revision Note No information available

Disclaimer

The information provided in this Material Safety Data Sheet is correct to the best of our knowledge, information and belief at the date of its publication. The information given is designed only as a guidance for safe handling, use, processing, storage, transportation, disposal and release and is not to be considered a warranty or quality specification. The information relates only to the specific material designated and may not be valid for such material used in combination with any other materials or in any process, unless specified in the text.

End of Safety Data Sheet